Etsy to Announce First Quarter 2025 Financial Results on April 30, 2025

PR Newswire

BROOKLYN, N.Y., April 16, 2025 /PRNewswire/ — Etsy, Inc. (Nasdaq: ETSY), which operates two-sided online marketplaces that connect millions of passionate and creative buyers and sellers around the world, plans to release its first quarter 2025 financial results before the opening of the market on Wednesday, April 30, 2025. The press release can be accessed on the Etsy Investor Relations website (investors.etsy.com).

Etsy will also host a video webcast conference call to discuss those results at 8:30 a.m.  Eastern Time on the same day, which will be live-streamed via the Company’s Investor Relations website (investors.etsy.com) under the events section. Publishing research analysts will be provided an opportunity to ask company management live questions on the call. A copy of the earnings call presentation will also be posted to our website.

A replay of the video webcast will be available through the same link following the conference call starting at 12:00 p.m. Eastern Time that day, for at least three months thereafter.

About Etsy                                                    

Etsy, Inc. operates two-sided online marketplaces that connect millions of passionate and creative buyers and sellers around the world. These marketplaces share a mission to “Keep Commerce Human,” and we’re committed to using the power of business and technology to strengthen communities and empower people. Our primary marketplace, Etsy.com, is the global destination for unique and creative goods. Buyers come to Etsy to be inspired and delighted by items that are crafted and curated by creative entrepreneurs. For sellers, we offer a range of tools and services that address key business needs.

Etsy, Inc.’s “House of Brands” portfolio also includes fashion resale marketplace Depop, and Reverb, the largest online marketplace dedicated to music gear. Each Etsy, Inc. marketplace operates independently, while benefiting from shared expertise in product, marketing, technology, and customer support.

Etsy was founded in 2005 and is headquartered in Brooklyn, New York.

Etsy has used, and intends to continue using, its Investor Relations website and the Etsy News Blog (etsy.com/news) to disclose material non-public information and to comply with its disclosure obligations under Regulation FD. Accordingly, you should monitor our investor relations website and the Etsy News Blog in addition to following our press releases, SEC filings, and public conference calls and webcasts.

Investor Relations Contact:
Deb Wasser, Vice President of Investor Relations
Sarah Marx, Senior Director, Investor Relations
[email protected] 

Media Relations Contact:
Lauren Bayse, Senior Director, Corporate Communications
[email protected]

Cision View original content:https://www.prnewswire.com/news-releases/etsy-to-announce-first-quarter-2025-financial-results-on-april-30-2025-302430435.html

SOURCE Etsy, Inc.

Opera to Announce First Quarter 2025 Financial Results on April 28, 2025

PR Newswire


OSLO, Norway
, April 16, 2025 /PRNewswire/ — Opera Limited (NASDAQ: OPRA), one of the world’s major browser developers and a leading internet consumer brand, announced today that the company’s first quarter 2025 financial results will be released before the market opens on Monday, April 28, 2025. The earnings release will be available on our investor relations website at investor.opera.com.

Management will host a conference call to discuss the first quarter 2025 financial results on the same day at 8:00 a.m. ET. Listeners may access the call by dialing the following numbers:

United States: +1 800-225-9448
Norway: +47 80-01-3780
International: +1 203-518-9708

Confirmation Code: OPRAQ125

A live webcast of the conference call can be accessed at investor.opera.com

About Opera
Opera is a user-centric and innovative software company focused on enabling the best possible internet browsing experience across all devices. Hundreds of millions use the Opera web browsers for their unique and secure features on their mobile phones and desktop computers. Founded in 1995, and headquartered in Oslo, Norway, Opera is a public company listed on the Nasdaq stock exchange under the ticker symbol “OPRA”. Download the Opera web browser and access other Opera products from opera.com. Learn more about Opera at investor.opera.com.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/opera-to-announce-first-quarter-2025-financial-results-on-april-28-2025-302430566.html

SOURCE Opera Limited

Sands to Release First Quarter 2025 Financial Results

PR Newswire


LAS VEGAS
, April 16, 2025 /PRNewswire/ — Las Vegas Sands (NYSE: LVS) will release its first quarter 2025 financial results on Wednesday, April 23, 2025, after market close.

The company will host a conference call to discuss its results at approximately 1:30 p.m. Pacific Time.

A webcast of the conference call will be available at www.investor.sands.com.   

About Sands (NYSE:

LVS

)

Sands is the leading global developer and operator of integrated resorts. The company’s iconic properties drive valuable leisure and business tourism and deliver significant economic benefits, sustained job creation, financial opportunities for local businesses and community investment to help make its host regions ideal places to live, work and visit.

Sands’ portfolio of properties includes Marina Bay Sands® in Singapore and The Venetian®MacaoThe Londoner Macao®The Parisian Macao®, The Plaza Macao and Four Seasons Hotel Macao, and Sands®Macao in Macao SAR, China, through majority ownership in Sands China Ltd. 

Dedicated to being a leader in corporate responsibility, Sands is anchored by the core tenets of serving people, communities and the planet. The company’s ESG leadership has led to inclusion on the Dow Jones Sustainability Indices for World and North America, as well as Fortune’s list of the World’s Most Admired Companies. To learn more, visit www.sands.com.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/sands-to-release-first-quarter-2025-financial-results-302430819.html

SOURCE Las Vegas Sands Corp.

Accuray to Report Third Quarter Fiscal 2025 Financial Results on April 30, 2025

PR Newswire


MADISON, Wis.
, April 16, 2025 /PRNewswire/ — Accuray Incorporated (NASDAQ: ARAY) will report financial results for the third quarter of fiscal year 2025, ended March 31, 2025, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on April 30, 2025.

The conference call dial-in numbers are 1-833-316-0563 (USA) or 1-412-317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call’s conclusion for one week. The replay number is 1-877-344-7529 (USA) or 1-412-317-0088 (international), conference ID: 8141169.

A live webcast of the call will also be available from the Investor Relations section of the company’s website at investors.accuray.com. A webcast replay can be accessed on the website and will remain available until Accuray announces its results for the fourth quarter of fiscal 2025.

About Accuray
Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives faster. Accuray is headquartered in Madison, Wisconsin, with facilities worldwide. To learn more, visit www.accuray.com or follow us on Facebook, LinkedIn, X, and YouTube.

Investor Contact

Aman Patel, CFA
Investor Relations, ICR Healthcare
+1 (443) 450-4191
[email protected] 

Media Contact

Beth Kaplan

Public Relations Director, Accuray
+1 (408) 789-4426
[email protected]

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/accuray-to-report-third-quarter-fiscal-2025-financial-results-on-april-30-2025-302429891.html

SOURCE Accuray Incorporated

Alexander & Baldwin Announces Ground Lease at Maui Business Park

PR Newswire


HONOLULU
, April 16, 2025 /PRNewswire/ — Alexander & Baldwin, Inc. (NYSE: ALEX) (“A&B” or “Company”), a Hawai’i-based owner, operator, and developer of high-quality commercial real estate in Hawai’i, announced the execution of a 75-year ground lease for 4.7 acres at its Maui Business Park Phase II project in Kahului, Maui. The lease agreement is with a prominent self-storage developer.

“I am pleased with the robust commercial activity and strong interest we continue to see at Maui Business Park,” said Lance Parker, president and chief executive officer. “This long-term ground lease represents a capital-efficient approach to expanding our portfolio and transforming non-income generating land into a productive asset. With this new relationship, we have an opportunity to invest in the development of the asset as well. Alongside our ongoing build-to-suit development project, this agreement demonstrates our commitment to strategically enhancing our commercial real estate portfolio and delivering value to our investors, tenants, and the local community.”

ABOUT MAUI BUSINESS PARK PHASE II

Maui Business Park Phase II is a 125-acre, mixed-use development near the Kahului Harbor and Kahului Airport, with immediate and easy access to all parts of Maui Island. The park has successfully attracted national, regional, and local businesses, establishing itself as Maui’s prime neighborhood retail and industrial submarket. Leasing and sales are underway for lots ranging from one-half to five acres located within an Opportunity Zone, affording potential tax deferral benefits to qualified land purchasers. For more information on parcels available for sale or leasing opportunities at Maui Business Park Phase II, visit https://www.mauibusinessparkphase2.com or contact Bill Froelich at [email protected].

ABOUT ALEXANDER & BALDWIN
Alexander & Baldwin, Inc. (NYSE: ALEX) (A&B) is the only publicly-traded real estate investment trust to focus exclusively on Hawai’i commercial real estate and is the state’s largest owner of grocery-anchored, neighborhood shopping centers. A&B owns, operates and manages approximately 4.0 million square feet of commercial space in Hawai’i, including 21 retail centers, 14 industrial assets and four office properties, as well as 146 acres of ground lease assets. Over its 155-year history, A&B has evolved with the state’s economy and played a leadership role in the development of the agricultural, transportation, tourism, construction, residential and commercial real estate industries.

FORWARD-LOOKING STATEMENTS
Statements in this release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and involve a number of risks and uncertainties that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding possible or assumed future results of operations, business strategies, growth opportunities and competitive positions. Such forward-looking statements speak only as of the date the statements were made and are not guarantees of future performance. Forward-looking statements are subject to a number of risks, uncertainties, assumptions and other factors that could cause actual results and the timing of certain events to differ materially from those expressed in or implied by the forward-looking statements. These factors include, but are not limited to, prevailing market conditions and other factors related to the Company’s REIT status and the Company’s business, the evaluation of alternatives by the Company related to its non-core assets and business, and the risk factors discussed in the Company’s most recent Form 10-K, Form 10-Q and other filings with the Securities and Exchange Commission. The information in this release should be evaluated in light of these important risk factors. We do not undertake any obligation to update the Company’s forward-looking statements.

Learn more about A&B at www.alexanderbaldwin.com.

Media Contact: 

Andrea Galvin

[email protected]

Investor Contact:

Jordan Hino

[email protected]

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/alexander–baldwin-announces-ground-lease-at-maui-business-park-302430041.html

SOURCE Alexander & Baldwin, Inc.

WHIRLPOOL CORPORATION TO ANNOUNCE FIRST-QUARTER RESULTS ON APRIL 23RD AND HOLD CONFERENCE CALL ON APRIL 24TH

PR Newswire


BENTON HARBOR, Mich.
, April 16, 2025 /PRNewswire/ — Whirlpool Corporation (NYSE: WHR) will release its first-quarter financial results and presentation materials at 4:05 p.m. ET on Wednesday, April 23, 2025. Whirlpool Corporation will hold a conference call to discuss its performance with the investment community at 8 a.m. ET on Thursday, April 24, 2025.

To participate in the conference call, dial 1 (888) 440-4038 and Conference ID 2610251. International participants should dial 1 (646) 960-0861 and Conference ID 2610251. Participants should dial in at least 10 minutes prior to the call, as they may experience longer than usual wait times.

The conference call will be webcast live on the Company’s website at investors.whirlpoolcorp.com and may be accessed by clicking on the “News & Events” tab located at the top of the page, and by clicking on “Events & Presentations”. To listen to the live webcast, participants should visit the site at least 15 minutes prior to the conference call to download any required streaming media software. Key financial statistics, the earnings presentation, and an archived recording of the conference call will be available on the Company’s website for at least 30 days.

About Whirlpool Corporation
Whirlpool Corporation (NYSE: WHR) is a leading home appliance company, in constant pursuit of improving life at home. As the last-remaining major U.S.-based manufacturer of kitchen and laundry appliances, the company is driving meaningful innovation to meet the evolving needs of consumers through its iconic brand portfolio, including Whirlpool, KitchenAid, JennAir, Maytag, Amana,Brastemp, Consul, and InSinkErator. In 2024, the company reported approximately $17 billion in annual sales – close to 90% of which were in the Americas – 44,000 employees, and 40 manufacturing and technology research centers. Additional information about the company can be found at WhirlpoolCorp.com.

Website Disclosure
We routinely post important information for investors on our website, WhirlpoolCorp.com, in the “Investors” section. We also intend to update the Hot Topics Q&A portion of this webpage as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors should monitor the Investors section of our website, in addition to following our press releases, SEC filings, public conference calls, presentations and webcasts. The information contained on, or that may be accessed through, our webpage is not incorporated by reference into, and is not a part of, this document.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/whirlpool-corporation-to-announce-first-quarter-results-on-april-23rd-and-hold-conference-call-on-april-24th-302430664.html

SOURCE Whirlpool Corporation

Viking Therapeutics to Report Financial Results for First Quarter 2025 on April 23, 2025

PR Newswire


Conference Call Scheduled for Wednesday, April 23 at 4:30 p.m. Eastern Time


SAN DIEGO
, April 16, 2025 /PRNewswire/ — Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the first quarter 2025 after the market close on Wednesday, April 23, 2025.

The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on Wednesday, April 23, 2025. To participate on the conference call, please dial (844) 850-0543 from the U.S. or (412) 317-5199 from outside the U.S. In addition, following the completion of the call, a telephone replay will be accessible until April 30, 2025, by dialing (877) 344-7529 from the U.S. or (412) 317-0088 from outside the U.S. and entering replay access code #8779272. Those interested in listening to the conference call live via the internet may do so by visiting the Webcasts page of Viking’s website at http://ir.vikingtherapeutics.com/webcasts. An archive of the webcast will also be available on the Webcasts page of the company’s website for 30 days.

About Viking Therapeutics, Inc. 

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. Viking’s research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients’ lives. Viking’s clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. Data from a Phase 1 and a Phase 2 trial evaluating VK2735 (dosed subcutaneously) for metabolic disorders demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit. Concurrently, the company is evaluating an oral formulation of VK2735 in a Phase 2 trial. Viking is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. The compound successfully achieved both the primary and secondary endpoints in a recently completed Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company’s newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists (or DACRAs) for the treatment of obesity and other metabolic disorders.  In the rare disease space, Viking is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD).  In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids (VLCFAs) and other lipids, as compared to placebo.

For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-to-report-financial-results-for-first-quarter-2025-on-april-23-2025-302429383.html

SOURCE Viking Therapeutics, Inc.

Tripadvisor to Host First Quarter 2025 Financial Results Conference Call on May 7, 2025

PR Newswire


NEEDHAM, Mass.
, April 16, 2025 /PRNewswire/ — Tripadvisor, Inc. (NASDAQ: TRIP) announced today that at 7:05 a.m. ET on Wednesday, May 7, 2025, the company will post its first quarter 2025 financial results on its investor relations website at ir.tripadvisor.com.

The same day, at 8:30 a.m. ET, the company will host a conference call to answer questions regarding its financial results.  The event will be webcast live and can be accessed at ir.tripadvisor.com.  A replay will be available on the website for three months.

About Tripadvisor, Inc.
The Tripadvisor Group connects people to experiences worth sharing, and aims to be the world’s most trusted source for travel and experiences. We leverage our brands, technology, and capabilities to connect our global audience with partners through rich content, travel guidance, and two-sided marketplaces for experiences, accommodations, restaurants, and other travel categories. The subsidiaries of Tripadvisor, Inc. (Nasdaq: TRIP), include a portfolio of travel brands and businesses, including Tripadvisor, Viator, and TheFork.

TRIP-G

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/tripadvisor-to-host-first-quarter-2025-financial-results-conference-call-on-may-7-2025-302429287.html

SOURCE Tripadvisor

ACM Research to Release First Quarter 2025 Preliminary Revenue Range on April 29, 2025 and Full Financial Results on May 8, 2025

FREMONT, Calif., April 16, 2025 (GLOBE NEWSWIRE) — ACM Research, Inc. (“ACM”) (NASDAQ: ACMR) announced today that it will release its preliminary revenue range for the first quarter of 2025 before the U.S. market open on Tuesday, April 29, 2025, to coincide with reporting obligations of ACM Research (Shanghai), Inc., ACM’s principal operating subsidiary, to the Shanghai Stock Exchange.

ACM will release its full financial results for the first quarter of 2025 before the U.S. market open on Thursday, May 8, 2025. ACM will conduct a corresponding conference call at 8:00 a.m. U.S. Eastern Time (8:00 p.m. China Time) to discuss the results.

What: ACM First Quarter (ended March 31, 2025) Earnings Call
When: 8:00 a.m. U.S. Eastern Time on Thursday, May 8, 2025
Webcast: ir.acmr.com/news-events/events


To join the conference call via telephone, participants must use the following link to complete an online registration process. Upon registering, each participant will receive email instructions to access the conference call, including dial-in information and a PIN number allowing access to the conference call. This pre-registration process is designed by the operator to reduce delays due to operator congestion when accessing the live call.

Online Registration:
https://register-conf.media-server.com/register/BI300a7bc629bd43d98fcb1268d481b156

Participants who have not pre-registered may join the webcast by accessing the link at ir.acmr.com/news-events/events.

A live and archived webcast of the conference call will be available on the Investors section of ACM’s website at www.acmr.com.

About ACM Research, Inc.

ACM develops, manufactures and sells semiconductor process equipment spanning cleaning, electroplating, stress-free polishing, vertical furnace processes, track, PECVD, and wafer- and panel-level packaging tools, enabling advanced and semi-critical semiconductor device manufacturing. ACM is committed to delivering customized, high-performance, cost-effective process solutions that semiconductor manufacturers can use in numerous manufacturing steps to improve productivity and product yield. For more information, visit www.acmr.com.

© ACM Research, Inc. The ACM Research logo is a trademark of ACM Research, Inc. For convenience, this trademark appears in this press release without a ™ symbol, but that practice does not mean that ACM will not assert, to the fullest extent under applicable law, its rights to such trademark.

For investor and media inquiries, please contact:

In the United States: The Blueshirt Group
  Steven C. Pelayo, CFA
  +1 (360) 808-5154
  [email protected]
In China: The Blueshirt Group Asia
  Gary Dvorchak, CFA
  +86 (138) 1079-1480
  [email protected]



Elicio Therapeutics Reports Inducement Grant to New Chief Strategy and Financial Officer and Other New Hires

BOSTON, April 16, 2025 (GLOBE NEWSWIRE) — Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on April 15, 2025, Elicio granted inducement awards to Elicio’s newly appointed Chief Strategy and Financial Officer, Preetam Shah, and two additional new employees, as an inducement material to Dr. Shah and such employees entering into employment with Elicio in accordance with Nasdaq Listing Rule 5635(c)(4), which grants were approved by the compensation committee of Elicio’s board of directors in accordance with the Elicio 2024 Inducement Incentive Award Plan.

The grant to Dr. Shah provides for the issuance of 191,624 stock options. Additionally, the grants to the two employees provide for the issuance of an aggregate of 21,000 stock options. Each grant provides for the purchase of shares of Elicio common stock at a price of $4.98 per share, the closing price per share of Elicio common stock as reported by Nasdaq on April 15, 2025, the date of each grant.

Each of the grants vest over four years, with 25 percent of the shares vesting on the first anniversary of Dr. Shah’s and each employee’s respective start date, and the remainder vesting ratably at the end of each subsequent month thereafter, subject to such individual’s continued service relationship with Elicio through the applicable vesting dates.

About Elicio Therapeutics

Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of high-prevalence cancers, including mKRAS-positive pancreatic and colorectal cancers. Elicio intends to build on recent clinical successes in the personalized cancer vaccine space to develop effective, off-the-shelf vaccines. Elicio’s Amphiphile (“AMP”) technology aims to enhance the education, activation and amplification of cancer-specific T cells relative to conventional vaccination strategies, with the goal of promoting durable cancer immunosurveillance in patients. Elicio’s ELI-002 lead program is an off-the-shelf vaccine candidate targeting the most common KRAS mutations, which drive approximately 25% of all solid tumors. ELI-002 is being studied in an ongoing, randomized clinical trial in patients with mKRAS-positive pancreatic cancer who completed standard therapy but remain at high risk of relapse. Elicio’s pipeline includes additional off-the-shelf therapeutic cancer vaccines, including ELI-007 and ELI-008, that target BRAF-driven cancers and p53 hotspot mutations, respectively. For more information, please visit www.elicio.com.

Investor Relations Contact

Brian Ritchie
LifeSci Advisors, LLC
(212) 915-2578